Logo
  • About
  • Technology
  • News
  • Contact
Logo
  • About
  • Technology
  • News
  • Contact
01
Oct
2018

Paul Little, Operating Partner in Lundbeckfonden Emerge, replaces Christian Elling as CEO of Insusense Therapeutics

News

Come meet us at DK Bio 2019
20. February 2019
7-11 January 2019: Meet Insusense Therapeutics in San Francisco at this year’s JP Morgan biotech conference
7. January 2019
Insusense Therapeutics website launches
4. January 2019
Lundbeck Foundation doubles its investment in Aarhus-based Insusense Therapeutics
20. October 2015

About Us

InsuSence Therapeutics is a product-focused biotechnology company based on novel breakthrough science in diabetes biology, which has the potential to quantum leap to important new Type 2 diabetes therapeutics.

News

Come meet us at DK Bio 2019
20. February 2019
7-11 January 2019: Meet Insusense Therapeutics in San Francisco at this year’s JP Morgan biotech conference
7. January 2019
Insusense Therapeutics website launches
4. January 2019

Contact

Insusense ApS
c/o Lundbeckfonden
Scherfigsvej 7
DK-2100 Copenhagen

  • Privacy Policy
Copyright © InsuSense Therapeutics, All Rights Reserved.